Neovir 250 mg/2 ml 2 ml, 3 pcs.

Neovir is an immunomodulatory, antiviral.

Induces formation in the body of high titers of endogenous interferons, especially interferon alpha.

Pharmacodynamics

It has antiviral (against DNA- and RNA-genomic viruses) and pronounced antichlamydial action. Activates bone marrow stem cells, T-lymphocytes and macrophages. It normalizes the balance between subpopulations of T-helper and T-suppressor cells.

In HIV-infection it has an immunomodulatory effect: increases the absorptive activity of serum, increases the ability of leukocytes to synthesize interferon alpha, stimulates the formation of reactive oxygen species by phagocytes.

The peak of interferon activity in blood and tissues is observed several hours after I/m injection and lasts for 16-20 hours. Injection of 250 mg of Neovirinum per month is equivalent to 6-9 million IU of recombinant interferon alfa by dynamics of serum interferon titer.

Pharmacokinetics

T1/2 – 1 h, excreted unchanged in the urine.

Indications

Prevention and treatment of influenza and other acute respiratory diseases of viral etiology (including in persons with immunodeficiency);

– infections caused by Herpes simplex, Herpes simplex genitalis, Herpes Varicella zoster viruses (including in people with impaired immune systems);

– CMV infection against the background of immunodeficiency;

– radiation immunodeficiency;

– immunodeficiency conditions, including HIV infection;

– encephalitis and encephalomyelitis of viral etiology;

– acute and chronic hepatitis B and C;

– urethritis, epididymitis, prostatitis, cervicitis and salpingitis of chlamydial etiology;

– lymphogranuloma venereum;

– oncological diseases (combination therapy);

– multiple sclerosis;

– candidal lesions of the skin and mucous membranes.

Pharmacological effect

Neovir – immunomodulatory, antiviral.

Induces the formation in the body of high titers of endogenous interferons, especially interferon alpha.

Pharmacodynamics

It has antiviral (against DNA and RNA genomic viruses) and a pronounced antichlamydial effect. Activates bone marrow stem cells, T-lymphocytes and macrophages. Normalizes the balance between subpopulations of T-helper and T-suppressor cells.

Capable of reducing the production of tumor necrosis factor (for HIV infection, herpes), and activating natural killer cells (for tumor diseases). It has a pronounced stimulating effect on the activity of polymorphonuclear leukocytes.

In case of HIV infection, it has an immunomodulatory effect: it increases the absorption activity of serum, increases the ability of leukocytes to synthesize interferon alpha; stimulates the formation of reactive oxygen species by phagocytes.

The peak of interferon activity in the blood and tissues is observed several hours after intramuscular administration and persists for 16–20 hours. In terms of the dynamics of the serum interferon titer, an injection of 250 mg of Neovir intramuscularly is equivalent to the administration of 6–9 million IU of recombinant interferon alpha.

Pharmacokinetics

T1/2 – 1 hour, excreted unchanged in urine.

Special instructions

In case of poor tolerance or pain at the site of intramuscular injection of the drug, it is recommended to administer Neovir together with 2 ml of 0.25-0.5% novocaine solution.

Active ingredient

Sodium oxodihydroacridinyl acetate

Composition

1 ml – sodium oxodihydroacridinyl acetate 125 mg.

Excipients:

sodium citrate 2.5 mg,

citric acid monohydrate 0.5-1.5 mg (up to pH 7.5-8.3),

water for up to 1 ml.

Contraindications

Hypersensitivity, chronic renal failure II–III degree, pregnancy, breastfeeding, childhood.

Side Effects

General reactions: low-grade fever, allergic reactions.

Local reactions: local, quickly passing pain at the injection site.

Interaction

During clinical trials and use of the drug in clinical practice, there were no cases of incompatibility or potentiation of the drug’s effect when interacting with other drugs.

There is no information on the physicochemical incompatibility of Neovir with other drugs.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

3 years

Manufacturer

Federal State Budgetary Institution National Medical Research Center of Cardiology, Russia